Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

XBIO vs DRIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XBIO Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 6–4 Matrix Metrics)

XBIO Overall Winner 6-Pillar Tally: XBIO 2 – 2 DRIO (2 Tie) Matrix Metrics: XBIO 6 – 4 DRIO

As of Nov 20, 2026, Xenetic Biosciences, Inc. (XBIO) is the stronger overall head-to-head candidate over DarioHealth Corp. (DRIO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). XBIO carries a Unified Composite Score of 43.5/100 (HOLD) at $1.40 (N/M Forward P/E, -81.0% operating margin), whereas DRIO carries 42.2/100 (HOLD) at $1.32 (10.6x Forward P/E, -142.7% operating margin).

  • Technical & Structure Timing Caution: XBIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.9); meanwhile DRIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About XBIO vs DRIO
XBIO NASDAQ Head-to-Head Winner
Xenetic Biosciences, Inc.
Pharmaceutical Preparations
$1.40
-9.09% 1D
Market Cap $3.6M
TTM Revenue $3.3M
Forward P/E N/M
Beta / 30D Vol 1.40β · 99% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 25.0 Fund 56.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -28.1%), weak momentum, RSI 30
RSI-14: 29.9 · SMA20: $1.81 · SMA50: $2.14
DRIO NASDAQ
DarioHealth Corp. Common Stock
Surgical & Medical Instruments & Apparatus
$1.32
-8.33% 1D
Market Cap $16.3M
TTM Revenue $21M
Forward P/E 10.6x
Beta / 30D Vol 0.45β · 182% Vol
Unified Composite Score
42.2 / 100 HOLD
Tech 50.0 Fund 52.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -30.0%), weak momentum, RSI 24
RSI-14: 24.0 · SMA20: $2.34 · SMA50: $4.46

6-Pillar Scorecard Institutional Category Breakdown (XBIO 2 – 2 DRIO)

Columns: Metric · XBIO · DRIO
1. Valuation Multiples DRIO
Forward P/E N/M 10.6x
Trailing P/E N/M 10.6x
PEG Ratio N/M N/M
EV / Revenue 1.1x 0.8x
2. Growth & Scale DRIO
Revenue Growth (YoY) +12.0% +6.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $3.3M $21M
Market Cap $3.6M $16.3M
3. Profitability & Quality XBIO
Gross Margin 100.0% 61.3%
Operating Margin -81.0% -142.7%
Net Profit Margin -75.9% -159.9%
Return on Equity (ROE) -47.0% -46.6%
4. Balance Sheet & Cash Flow XBIO
Cash Generation (TTM) -$1.8M -$28M EBITDA
Cash Flow Margin -55.8% -132.8% EBITDA Mgn
Net Cash / Leverage $3.23 Book/Sh · -47.0% ROE $6.37 Book/Sh · -46.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Health Information Services Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: XBIO (6) vs DRIO (4)
Institutional Metric XBIO DRIO Criterion Row Edge
Market Capitalization
Scale
$3.6M $16.3M Larger Scale DRIO
Trailing P/E Ratio
Valuation
N/M 10.6x Lower Multiple DRIO
Forward P/E Ratio
Valuation
N/M 10.6x Lower Multiple DRIO
Revenue Growth (YoY)
Growth
+12.0% +6.1% Higher Growth XBIO
Operating Margin (TTM)
Profitability
-81.0% -142.7% Higher Margin XBIO
Net Profit Margin
Profitability
-75.9% -159.9% Higher Margin XBIO
Return on Equity (ROE)
Capital Efficiency
-47.0% -46.6% Higher ROE DRIO
52-Week Range Position
Momentum
4% ($1–$5) 2% ($1–$15) Stronger Trend XBIO
Beta / 30D Volatility
Risk Regime
1.40β · 99% Vol 0.45β · 182% Vol Lower Realized Risk XBIO
Unified Institutional Score
Composite Signal
43.5 / 100 (HOLD) 42.2 / 100 (HOLD) Higher Composite XBIO
Trailing 12M Revenue (USD)
Operating Scale
$3.3M $21M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 61.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.1x EV/Rev N/M PEG · 0.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$1.8M ($3.23 Book/Sh · -47.0% ROE) -$28M EBITDA ($6.37 Book/Sh · -46.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon XBIO +33.83 pp
XBIO: -27.46% · DRIO: -61.29%
3M Horizon XBIO +18.44 pp
XBIO: -63.25% · DRIO: -81.69%
6M Horizon XBIO +29.43 pp
XBIO: -53.78% · DRIO: -83.21%
1Y Horizon XBIO +45.69 pp
XBIO: -44.88% · DRIO: -90.57%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XBIO vs DRIO. Trailing 12-month operating profitability (XBIO -81.0% vs DRIO -142.7%) and valuation multiples (XBIO N/M vs DRIO 10.6x Forward P/E) are benchmarked directly in Pillar 4 below.

XBIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.3M
Gross Margin100.0%
Op. Margin-81.0%
ROE / Fwd P/E-47.0% · N/M
DRIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$21M
Gross Margin61.3%
Op. Margin-142.7%
ROE / Fwd P/E-46.6% · 10.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
XBIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DRIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DRIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
XBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.6M market capitalization and -81.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DRIO Moat Profile Cyclical / Execution-Driven Positioning
Health Information Services Operator
Competes within the Health Information Services value chain with $16.3M market capitalization and -142.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ XBIO vs DRIO Key Questions & Quantitative Answers

As of Nov 20, 2026, Xenetic Biosciences, Inc. (XBIO) is the stronger overall head-to-head candidate over DarioHealth Corp. (DRIO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). XBIO carries a Unified Composite Score of 43.5/100 (HOLD) at $1.40 (N/M Forward P/E, -81.0% operating margin), whereas DRIO carries 42.2/100 (HOLD) at $1.32 (10.6x Forward P/E, -142.7% operating margin). Technical & Structure Timing Caution: XBIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.9); meanwhile DRIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DRIO leads the Growth & Scale pillar: XBIO posts +12.0% YoY revenue growth and +0.0% YoY earnings growth on $3.3M TTM revenue (100.0% gross margin, -81.0% operating margin), compared with DRIO at +6.1% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.3% gross margin, -142.7% operating margin). On trailing 12-month operating scale, XBIO generates $3.3M in USD-normalized revenue versus $21M for DRIO. In operating R&D and SG&A reinvestment, XBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DRIO.

DRIO screens cheaper on headline valuation multiples. XBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-55.8% FCF margin), whereas DRIO trades at 10.6x Forward P/E, 10.6x Trailing P/E, N/M PEG, and 0.8x EV/Revenue (-132.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XBIO (-47.0% ROE) versus DRIO (-46.6% ROE) capital efficiency.

In options market volatility and institutional positioning, XBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.40β · 99% Vol realized risk). By comparison, DRIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.45β · 182% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.